Nippon Shinyaku’s Duchenne muscular dystrophy (DMD) therapeutic Viltepso (viltolarsen) has managed to build a growing sales position in the US market over the five years since its launch, despite clinical setbacks and legal challenges involving the main player in the sector.
This was borne out in the mid-sized Japanese firm’s recently reported earnings for the fiscal third quarter ended 31 December, when it revised upwards its US full fiscal year sales forecast for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?